---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-017306"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:24:20.047634+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dyadic regains Nasdaq compliance, achieves $750K in milestones with Proliant & Inzymes

## Summary
- Regained compliance with Nasdaq market value ($35M) and bid price ($1.00) rules after 10 consecutive days ending Sept 30 & Oct 2, 2025.
- Received $500K milestone from Proliant for recombinant human albumin productivity; payment expected Q4 2025; commercial launch targeted late 2025/early 2026.
- Received $250K milestone payment from Inzymes for dairy enzyme productivity improvements; first enzyme scale-up on track for late 2025 launch.
- Signed term sheet for development of non-animal human alpha-lactalbumin for infant nutrition; sampling of bovine version underway.
- Advancing commercialization of recombinant transferrin and DNase I with ongoing sampling and validation in research/diagnostic markets.

## SEC filing metadata
- accession: 0001493152-25-017306
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000149315225017306/0001493152-25-017306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000149315225017306/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-017306
- JSON: https://secwatch.observer/filing/0001493152-25-017306.json
- Plain text: https://secwatch.observer/filing/0001493152-25-017306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.